Clinical trials
Hematopoietic Stem Cell Transplantation clinical trials
Below are recruiting hematopoietic stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 374 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07249346RecruitingPhase 2
Preventing GVHD after stem cell transplant with three drugs
This trial tests a three-drug combination (cyclophosphamide, tacrolimus, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people with certain blood cancers who have a matched donor and can tolerate high-dose chemotherapy.
Columbus, OhioAges 18 years+ - NCT05531786RecruitingPhase 1/Phase 2
Pacritinib for hard-to-treat chronic graft-versus-host disease
This early-phase study tests pacritinib, a targeted medicine, for chronic graft-versus-host disease (cGVHD) that hasn’t improved after prior treatments. If you qualify, the goal is to reduce cGVHD symptoms and improve how well you function after a stem cell transplant.
Miami, FloridaAges 18–120 - NCT07680933RecruitingPhase 2
Orelabrutinib plus chemo for newly diagnosed DLBCL
This trial tests if adding orelabrutinib (a targeted pill) to standard chemotherapy, with or without a stem cell transplant, works better for people with a new diagnosis of diffuse large B-cell lymphoma. It may help patients who have a higher risk of the lymphoma coming back.
Xuzhou, JiangsuAges 18–80 - NCT07252050RecruitingPhase 1/Phase 2
Ruxolitinib and half-matched transplant for severe sickle cell disease
This trial tests a new approach using the drug ruxolitinib to help a half-matched bone marrow transplant work better for people with severe sickle cell disease. It aims to reduce complications and improve outcomes.
Aurora, ColoradoAges 12–45 - NCT07253129Recruiting
Stem cell transplant study for T-cell lymphoma patients with partial response
This study compares two types of stem cell transplants (from a donor or your own cells) for people with certain T-cell lymphomas who had only a partial response to first chemotherapy. It aims to see which approach may work better.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07256210RecruitingPhase 2
Donor NK cells to prevent leukemia return after stem cell transplant
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
MoscowAges 1 month–25 years - NCT07269041RecruitingPhase 1/Phase 2
Immune tolerance after liver transplant
This trial tests a way to help your body accept your liver transplant without needing lifelong anti-rejection drugs. It uses your living donor's stem cells to train your immune system to not attack the new liver.
Los Angeles, CaliforniaAges 18 years+ - NCT07284641RecruitingPhase 2
Stem cell transplant for immune disorders
This trial tests a stem cell transplant to treat common variable immunodeficiency (CVID) and other immune problems. It aims to replace a faulty immune system with a healthy one from a donor.
Pittsburgh, PennsylvaniaAges 5–40 - NCT07297303Recruiting
Lung health study after stem cell transplant
This study follows lung health after a stem cell transplant from a donor, to understand and manage chronic graft-versus-host disease (a condition where donor cells attack the body). It may help people who are about to have their first donor transplant.
TaipeiAges 18 years+ - NCT07301866RecruitingPhase 1/Phase 2
Testing an improved dose of UM171 for cord blood transplant
This trial tests a higher dose of UM171 to make cord blood transplants safer and more effective for people with certain blood cancers or bone marrow diseases. It aims to help patients who don't have a suitable donor.
Montreal, QuebecAges 18–67 - NCT06996119RecruitingPhase 1
Preventing graft-versus-host disease after stem cell transplant
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT07353840Recruiting
Personalized treatment for T-cell lymphoma after first complete remission
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07356245RecruitingPhase 2
Ruxolitinib after stem cell transplant for T-cell lymphoma
This trial tests whether taking ruxolitinib after a stem cell transplant can help prevent T-cell lymphoma from coming back. It is for patients whose lymphoma is in remission (partial or complete) after their transplant.
Columbus, OhioAges 18 years+ - NCT07362095RecruitingPhase 1/Phase 2
Luspatercept for anemia after a stem cell transplant
This study tests a drug called luspatercept to see if it can help people who have low red blood cells (anemia) after a stem cell transplant for leukemia. It may improve your energy and reduce the need for blood transfusions.
Guangzhou, GuangdongAges 18–70 - NCT07365306RecruitingPhase 2
Epcoritamab with chemo before stem cell transplant for DLBCL
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
Duarte, CaliforniaAges 18 years+ - NCT07366801RecruitingPhase 2/Phase 3
Preventing graft versus host disease in children with blood cancer
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
MoscowAges 1–25 - NCT07368634RecruitingPhase 1/Phase 2
EBV-TCR-T cells for persistent EBV after stem cell transplant
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
BeijingAges 18–70 - NCT01890486Recruiting
Collecting information from people having a stem cell transplant
This study aims to collect, store, and share data from patients who are receiving standard intensive treatment and a stem cell transplant from either their own cells or a donor. It may help improve how future patients are treated by building a reliable record of outcomes and care patterns.
Winston-Salem, North CarolinaAges 18–120 - NCT00001405Recruiting
Blood Cell Collection Study for Immune and Blood Disorders
This study collects blood cells and bone marrow from people with immune system or blood disorders, and from healthy volunteers. Researchers will study these cells and may convert them into special stem cells (iPS cells) to better understand diseases and develop treatments.
Bethesda, MarylandAges 18–70 - NCT02007356RecruitingPhase 2
Donor immune cell infusions for viral infections after stem cell transplant
This trial studies whether directly infusing donor-made immune cells (virus-fighting T-cells) is safe and feasible in people who still have viral infections after a stem cell transplant. It may help your body control infections from adenovirus, CMV, or EBV when standard antiviral treatments aren’t working.
BaselAges 18–65 - NCT01174108RecruitingPhase 2
Stem cell transplant with donor T-cells for severe bone marrow failure
This Phase 2 study tests a specific type of donor stem cell transplant for severe bone marrow failure conditions, aiming to improve cure rates while reducing transplant risks. It includes people with diseases like severe aplastic anemia and certain bone marrow disorders, especially when standard transplant plans feel too risky.
Baltimore, MarylandAges 4–80 - NCT01420562Recruiting
Posaconazole medicine study in transplant patients with mouth sores
This study looks at how posaconazole (an antifungal medicine) moves through the body in people who recently had an allogeneic stem cell transplant and have mouth sores (mucositis). It may help clinicians choose the safest and most effective dosing for preventing serious fungal infections.
Leuven, Vlaams-BrabantAges 18–75 - NCT01861106RecruitingPhase 2
Bone marrow transplant for people with GATA2 gene changes
This trial tests whether an allogeneic bone marrow (stem cell) transplant can improve outcomes for people with GATA2 gene changes or “MonoMAC” syndrome. It aims to rebuild a healthier immune system in patients who have serious infections and immune cell deficiencies.
Bethesda, MarylandAges 6–70 - NCT02934477Recruiting
Transplant study for higher-risk myelofibrosis patients
This trial studies whether an allogeneic (donor) stem cell transplant can help people with higher-risk myelofibrosis (fibrosis in the bone marrow). It looks at outcomes in different donor types as determined by matching rules and patient risk level.
Minneapolis, MinnesotaAges 55 years+
Hear when a new Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematopoietic stem cell transplantation?
- Yes. Clin2 currently lists 374 recruiting hematopoietic stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematopoietic stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematopoietic stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Allogeneic Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Haploidentical Hematopoietic Stem Cell Transplantation
- Autologous Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cell Transplant
- Stem Cell Transplantation
- Hematopoetic Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.